Track 12: CAR T-cell therapy

In CAR T-cell therapy, T cells are extracted from the patient's blood and altered in the laboratory by adding a gene for a receptor (known as a chimeric antigen receptor, or CAR), which aids the T cells in adhering to a particular cancer cell antigen. The patient is subsequently given their CAR T cells back.

Each CAR is created for a particular cancer's antigen since many malignancies have various antigens. For instance, the cancer cells in some types of leukaemia or lymphoma express the antigen CD19. The CAR T-cell treatments used to treat these tumours are designed to bind to the CD19 antigen and will not be effective against tumours lacking this antigen.


    Related Conference of Track 12: CAR T-cell therapy

    December 09-10, 2024

    17th World Congress on Stem Cell Research

    Dubai, UAE
    May 19-20, 2025

    8th Global Conference on Cell and Gene Therapy

    Singapore City, Singapore
    June 16-17, 2025

    21st Global Summit on Stem Cell & Regenerative Medicine

    Frankfurt, Germany

    Track 12: CAR T-cell therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in